Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Precision Medicine in Advanced ESCC Refractory to Immunotherapy
NCT07653451Phase 3Not yet recruiting
- Sponsor
- Peking University Cancer Hospital & Institute
- Start
- Jul 2026
- Primary completion
- Dec 2027
01
Overview
A Phase 3 trial of afatinib, toripalimab, dalpiciclib, pyrotinib, camrelizumab in Esophageal Squamous Cell Carcinoma (ESCC), sponsored by Peking University Cancer Hospital & Institute. Planned start Jul 2026; status: not yet recruiting.
02
Drugs
afatinibtoripalimabdalpiciclibpyrotinibcamrelizumab
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on NCT07653451.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07653451.